nicotinamide-beta-riboside and pterostilbene

The prevalence of NAFLD is increasing globally and on a path to becoming the most frequent cause of chronic liver disease. Strategies for the prevention and treatment of NAFLD are urgently needed.. A 6-month prospective, randomized, double-blind, placebo-controlled clinical trial was conducted to assess the efficacy of daily NRPT (commercially known as Basis, a combination of nicotinamide riboside and pterostilbene) supplementation in 111 adults with NAFLD. The study consisted of three arms: placebo, recommended daily dose of NRPT (NRPT 1×), and a double dose of NRPT (NRPT 2×). NRPT appeared safe and well tolerated. At the end of the study, no significant change was seen in the primary endpoint of hepatic fat fraction with respect to placebo. However, among prespecified secondary outcomes, a time-dependent decrease in the circulating levels of the liver enzymes alanine aminotransferase (ALT) and gamma-glutamyltransferase (GGT) was observed in the NRPT 1× group, and this decrease was significant with respect to placebo. Furthermore, a significant decrease in the circulating levels of the toxic lipid ceramide 14:0 was also observed in the NRPT 1× group versus placebo, and this decrease was associated with a decrease in ALT in individuals of this group. A dose-dependent effect was not observed with respect to ALT, GGT, or ceramide 14:0 in the NRPT 2× group.. This study demonstrates that NRPT at the recommended dose is safe and may hold promise in lowering markers of hepatic inflammation in patients with NAFLD.

Topics: Adult; Alanine Transaminase; Double-Blind Method; gamma-Glutamyltransferase; Humans; Inflammation; Non-alcoholic Fatty Liver Disease; Prospective Studies

BACKGROUNDDuring aging, there is a functional decline in the pool of muscle stem cells (MuSCs) that influences the functional and regenerative capacity of skeletal muscle. Preclinical evidence has suggested that nicotinamide riboside (NR) and pterostilbene (PT) can improve muscle regeneration, e.g., by increasing MuSC function. The objective of this study was to investigate if supplementation with NR and PT (NRPT) promotes skeletal muscle regeneration after muscle injury in elderly individuals by improved recruitment of MuSCs.METHODSThirty-two elderly individuals (55-80 years of age) were randomized to daily supplementation with either NRPT (1,000 mg NR and 200 mg PT) or matched placebo. Two weeks after initiation of supplementation, skeletal muscle injury was induced by electrically induced eccentric muscle work. Skeletal muscle biopsies were obtained before, 2 hours after, and 2, 8, and 30 days after injury.RESULTSA substantial skeletal muscle injury was induced by the protocol and associated with release of myoglobin and creatine kinase, muscle soreness, tissue edema, and a decrease in muscle strength. MuSC content, proliferation, and cell size revealed a large demand for recruitment after injury, but this was not affected by NRPT. Furthermore, histological analyses of muscle fiber area, central nuclei, and embryonic myosin heavy chain showed no NRPT supplementation effect.CONCLUSIONDaily supplementation with 1,000 mg NR and 200 mg PT is safe but does not improve recruitment of the MuSC pool or other measures of muscle recovery in response to injury or subsequent regeneration in elderly individuals.TRIAL REGISTRATIONClinicalTrials.gov NCT03754842.FUNDINGNovo Nordisk Foundation (NNF17OC0027242) and Novo Nordisk Foundation CBMR.

Topics: Aged; Creatine Kinase, MM Form; Dietary Supplements; Humans; Muscle, Skeletal; Muscular Diseases; Myoglobin; Myosin Heavy Chains; Niacinamide; Pyridinium Compounds; Stilbenes

Preclinical studies have identified both NAD. We conducted a randomized, double-blind, placebo-controlled study of escalating doses of NRPT in 24 hospitalized patients with AKI. The study was comprised of four Steps during which NRPT (5 subjects) or placebo (1 subject) was given twice a day for 2 days. NRPT dosing was increased in each Step: Step 1250/50 mg, Step 2500/100 mg, Step 3750/150 mg and Step 41,000/200 mg. Blood NAD. AKI resulted in a 50% reduction in whole blood NAD. NCT03176628 , date of registration June 5th, 2017.

Topics: Acute Kidney Injury; Aged; Aged, 80 and over; Creatinine; Dose-Response Relationship, Drug; Double-Blind Method; Drug Combinations; Female; Glomerular Filtration Rate; Humans; Male; Middle Aged; NAD; Niacinamide; Pilot Projects; Pyridinium Compounds; Stilbenes

Oxidative stress-induced damage is a major mechanism in the pathophysiology of amyotrophic lateral sclerosis (ALS). A recent human clinical trial showed that the combination of nicotinamide riboside (NR) and pterostilbene (PT), molecules with potential to interfere in that mechanism, was efficacious in ALS patients. We examined the effect of these molecules in SOD1

Topics: Acetylcysteine; Amyotrophic Lateral Sclerosis; Animals; Antioxidants; Apoptosis; Cytokines; Female; Male; Metabolome; Mice, Inbred C57BL; Mice, Transgenic; Mitochondria; Motor Activity; Motor Neurons; Mutation; NAD; Nerve Degeneration; NF-E2-Related Factor 2; Niacinamide; Oxidation-Reduction; Pyridinium Compounds; Reactive Oxygen Species; Sirtuin 1; Sirtuin 3; Spinal Cord; Stilbenes; Superoxide Dismutase-1; Survival Analysis

Topics: Adult; Amyotrophic Lateral Sclerosis; Humans; Male; Niacinamide; Pyridinium Compounds; Stilbenes